CliffBio
small molecule

ORIAHNN (COPACKAGED)

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM

Loss of exclusivityAugust 2040latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameORIAHNN (COPACKAGED)
Active ingredientELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM
StrengthEQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2020
Marketing statusRX

Listed patents

PatentExpiresType
11690845August 2040use U-3655
11542239July 2039substance, product
12083227August 2038product
11045470March 2034use U-2842
10881659March 2034use U-2842
7419983July 2029substance, product
11459305November 2028product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ORIAHNN (COPACKAGED) patent cliff — loss of exclusivity August 2040 | CliffBio